Previous close | 0.1120 |
Open | 0.1002 |
Bid | 0.0000 x 460000 |
Ask | 0.0000 x 450000 |
Day's range | 0.1002 - 0.1090 |
52-week range | 0.0840 - 0.3320 |
Volume | |
Avg. volume | 251 |
Market cap | 16.949M |
Beta (5Y monthly) | 1.63 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1500 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
PARIS, February 06, 2024--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereafter "Valerio Therapeutics" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announces a reduction of the par value of its shares.
PARIS, January 31, 2024--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO)
PARIS, September 28, 2023--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereafter "Valerio Therapeutics" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today reports its consolidated half-year financial results to June 30, 2023, and provides an update on its activities.